(917) 310-3371
Changes in fat distribution can affect health, comfort and body image for someone living with HIV. Lipodystrophy can involve fat accumulation, fat loss or both.
Clarify whether the proposed service is diagnostic assessment, specialist input or Egrifta WR treatment. Ask your plan about the exact product, pharmacy route, authorization documentation, supplies, IGF-1/glucose tests and follow-up visits. The clinical indication is excess abdominal fat in eligible adults with HIV lipodystrophy; a general weight-loss request may not meet that indication or plan criteria. Bring HIV and fat-distribution records and safety history so the prescriber can substantiate the request. An authorization does not establish that a chosen location has specialist capacity or medication supply. Request a complete expected-cost assessment without assuming another patient's approval applies to you.
Changes in fat distribution can affect health, comfort and body image for someone living with HIV. Lipodystrophy can involve fat accumulation, fat loss or both. Excess visceral fat inside the abdomen differs from fat under the skin and from ordinary weight gain. A useful evaluation identifies the pattern and discusses symptoms, metabolic health and treatment goals. It should not assume every change is caused by the current HIV medication.
Seek evaluation for a persistent change in abdominal size or loss of fat from the face or limbs, especially if it affects comfort or daily life. New rapid abdominal swelling, severe pain, fluid symptoms or other illness needs prompt assessment for another cause. Age, pregnancy, cancer or pituitary history, diabetes and current medicines influence whether a treatment such as Egrifta WR is suitable.
Discuss where fat has changed, when it began, symptoms and what matters to you. Bring relevant HIV treatment history and prior evaluations, including changes made elsewhere.
The clinician examines the pattern, reviews weight and metabolic measures and decides whether imaging or specialist assessment is needed. Blood glucose, lipid and other tests are chosen for the clinical problem rather than a fixed cosmetic package.
Discuss lifestyle and metabolic care, whether the ART regimen needs specialist review, and medication for the specific indicated pattern. Do not stop an effective antiretroviral regimen to test whether body shape changes.
Agree on the intended benefit, safety tests, who manages HIV care and how the response will be reviewed. If Egrifta WR is chosen, daily injections and formulation-specific teaching are part of the plan.
Bring medication dates, prior photographs or measurements if you want to share them, laboratory results and cancer/endocrine history. Tell the clinician about changes in appetite, strength, fatigue or fluid retention. Ask which findings establish the diagnosis and which uncertainties remain. You do not need to accept a weight-loss plan that fails to address the actual fat-distribution concern.
Preserve HIV suppression while any ART change is considered. Egrifta WR has specific cancer, pituitary and pregnancy contraindications and requires IGF-1 and glucose monitoring. It is not a general obesity treatment, and cardiovascular benefit is not established. Severe pain, rapidly increasing swelling or unexplained systemic symptoms should not wait for a routine body-composition appointment.
Follow-up checks the symptom and fat-distribution goal, metabolic results and any treatment adverse effects. If a medicine is not helping sufficiently, the clinician reviews continued use and alternatives. Changes in body shape can affect mood and confidence; tell the team if distress is interfering with relationships or care so appropriate support can be considered.
Ask whether your visit is an initial assessment, specialist consultation or medication follow-up. Coverage may require documentation of the diagnosed condition and the proposed therapy. Medication, supplies, visits, metabolic testing and specialist referral are separate questions. Confirm the specialist appointment, authorization and intended treatment location for your actual plan.
No. A benefits estimate, an accepted insurance name or approval for one service does not guarantee payment for the entire care plan. Verify the exact plan, treating clinician and site, service codes, referral/authorization requirements, medication benefit and separate laboratory or administration charges. Ask for the written decision and expected personal cost before a nonurgent visit.
Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.
Bring medication dates, prior photographs or measurements if you want to share them, laboratory results and cancer/endocrine history. Tell the clinician about changes in appetite, strength, fatigue or fluid retention. Ask which findings establish the diagnosis and which uncertainties remain. You do not need to accept a weight-loss plan that fails to address the actual fat-distribution concern.
Discuss where fat has changed, when it began, symptoms and what matters to you. Bring relevant HIV treatment history and prior evaluations, including changes made elsewhere.
The clinician examines the pattern, reviews weight and metabolic measures and decides whether imaging or specialist assessment is needed. Blood glucose, lipid and other tests are chosen for the clinical problem rather than a fixed cosmetic package.
Discuss lifestyle and metabolic care, whether the ART regimen needs specialist review, and medication for the specific indicated pattern. Do not stop an effective antiretroviral regimen to test whether body shape changes.
Agree on the intended benefit, safety tests, who manages HIV care and how the response will be reviewed. If Egrifta WR is chosen, daily injections and formulation-specific teaching are part of the plan.
Your drug plan and pharmacy must confirm your coverage decision and price. Medicare drug coverage depends on your drug plan’s formulary and on the exact prescribed product. Ask whether prior authorization or other plan rules apply. Ask the plan and pharmacy to check WR or SV by name, the indicated HIV-lipodystrophy use and your expected cost for the prescribed supply. Ask separately about visits, supplies and IGF-1/glucose monitoring. A monthly medicine quote does not establish the total care cost, and an approval does not establish stock. Keep your HIV medicines going while this separate treatment is reviewed.
Choose the right appointment type to continue.
